Ipamorelin is very similar to the growth hormone releasing peptides (GHRPs) GHRP 2 and GHRP 6 in that it mimics ghrelin (the hunger hormone) and targets a specific HGH pulse. However, unlike other GHRPs, this peptide doesn’t affect the release of cortisol, acetylcholine, prolactin and aldosterone thereby minimizing side effects experienced with other GH therapies, such as increased hunger. Because there are virtually no negative side effects, Ipamorelin can be prescribed more aggressively and more frequently than other therapies without the risk of elevated cortisol and acetylcholine blood plasma levels. This helps optimize HGH levels for a longer period of time, leading to more successful health outcomes.


GHRP-6 brings about the effects you’d expect from heightened Growth Hormone and IGF-1 levels; increased fat loss and muscle building. It’s worth remembering that Growth Hormone and IGF-1 will not only promote greater muscle hypertrophy (enlargement of existing muscle fibres) but will also cause muscle hyperplasia – an increase in the actual number of muscle cells.
For example, if 100mcg more were to be administered after the first 100mcg (making the effective dose of 200mcg), then the second dose will achieve only 50% of what the first dose already did. A 100mcg more (making a total of 300mcg) will achieve only 25% more of the initial dose. This implies that, in order to increase the effect of the compound, only a little more of it can be successfully administered after the saturation dose.
The two peptides CJC 1295 Ipamorelin, are often used in conjunction for better results. Known individually as CJC 1295 and Ipamorelin, these peptides have similar roles, which we will look at later. But for now, the CJC 1295 and Ipamorelin combination, is chiefly used together because the production of growth hormone secretion is 10 times more effective than using them individually. This makes it convenient for most users, to guarantee quicker results. Above all, it is popular among athletes, bodybuilders and weightlifters in need of building strength or speeding up the recovery of an injury.
By increasing our own growth hormone levels (which normally decrease as we age), there is an increase in protein synthesis which subsequently stimulates muscle growth.  It leads to an increase in muscle mass, an increase in fat metabolism (fat loss), and increase in physical strength.  It is also helpful in skin ageing, and effective in reducing wrinkles.
It should be noted right off the bat that GHRP-6 doses are often normally (and ideally) combined with doses of a GHRH analogue, such as Mod GRF 1-29 (CJC-1295 without DAC) due to the synergistic effects and compatibility between the two, as previously mentioned in this profile. With that being said, the proper GHRP-6 doses do not change whether or not it is utilized with a GHRH. If an effective GHRP-6 dose is 100mcg, for example, then 100mcg of GHRP-6 should be administered whether the user is utilizing it alone or with Mod GRF 1-29. The term/phrase “saturation dose” or “saturation doses” can be heard a lot when peptides are discussed. A saturation dose is defined as a dose that will completely (or near completely) saturate the peptide’s target receptors. In GHRP-6’s case, this means the Ghrelin receptors located on the hypothalamus and the anterior pituitary.
It should be noted right off the bat that GHRP-6 doses are often normally (and ideally) combined with doses of a GHRH analogue, such as Mod GRF 1-29 (CJC-1295 without DAC) due to the synergistic effects and compatibility between the two, as previously mentioned in this profile. With that being said, the proper GHRP-6 doses do not change whether or not it is utilized with a GHRH. If an effective GHRP-6 dose is 100mcg, for example, then 100mcg of GHRP-6 should be administered whether the user is utilizing it alone or with Mod GRF 1-29. The term/phrase “saturation dose” or “saturation doses” can be heard a lot when peptides are discussed. A saturation dose is defined as a dose that will completely (or near completely) saturate the peptide’s target receptors. In GHRP-6’s case, this means the Ghrelin receptors located on the hypothalamus and the anterior pituitary.
Application would result in all current OTC paracetamol/ phenylephrine products being up-scheduled to S3. Applicant’s justification for changing current combination products from exempt or S2 to S3 is on theoretical basis only, and no evidence provided of clinical risk. Pharmacokinetic study found that co-administration of paracetamol with phenylephrine increased plasma phenylephrine levels – applicant says this has potential for cardiac safety risk in susceptible patients.
RT-PCR experiments shed light on the molecular mechanisms by which GHRP-6 appeared to modulate the fibrotic response. Among the genes studied (Table 1), GHRP-6 proved to significantly reduce TGFB1 and CTGF () expression, with no effect on PDGFB gene expression. An unexpected finding was that MMP3 appeared significantly reduced in the GHRP-6-treated wounds (). Most meaningfully is that PPARG expression became significantly elevated with GHRP-6 treatment (), as compared to placebo-treated wounds (Figure 7).
[D-Lys3]-GHRP6 (growth hormone releasing peptide 6) induces the secretion of growth hormone (GH). In the membrane of clonal GC somatotropes, this peptide elevates the number of functional voltage-gated Ca2+ and Na+ channels. Chronic treatment with this peptide causes an elevation in Na+ macroscopic current in bovine pituitary somatotropes in culture, which results in an increase in the release of GH.
It has been discovered that when GHRP-6 and insulin are administered simultaneously, GH response to GHRP-6 is increased (1). However, the consumption of carbohydrates and/or dietary fats, around the administration window of GH secretagogues significantly blunts the GH release. A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound, scientists are hoping to gain a better clinical understanding of the peptide through further research over the next few years.
×